Literature DB >> 19737106

The pathobiology of glioma tumors.

Candece L Gladson1, Richard A Prayson, Wei Michael Liu.   

Abstract

The ongoing characterization of the genetic and epigenetic alterations in the gliomas has already improved the classification of these heterogeneous tumors and enabled the development of rodent models for analysis of the molecular pathways underlying their proliferative and invasive behavior. Effective application of the targeted therapies that are now in development will depend on pathologists' ability to provide accurate information regarding the genetic alterations and the expression of key receptors and ligands in the tumors. Here we review the mechanisms that have been implicated in the pathogenesis of the gliomas and provide examples of the cooperative nature of the pathways involved, which may influence the initial therapeutic response and the potential for development of resistance.

Entities:  

Mesh:

Year:  2010        PMID: 19737106      PMCID: PMC2887670          DOI: 10.1146/annurev-pathol-121808-102109

Source DB:  PubMed          Journal:  Annu Rev Pathol        ISSN: 1553-4006            Impact factor:   23.472


  136 in total

1.  Loss of heterozygosity on chromosome 10 is more extensive in primary (de novo) than in secondary glioblastomas.

Authors:  H Fujisawa; R M Reis; M Nakamura; S Colella; Y Yonekawa; P Kleihues; H Ohgaki
Journal:  Lab Invest       Date:  2000-01       Impact factor: 5.662

2.  Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice.

Authors:  E C Holland; J Celestino; C Dai; L Schaefer; R E Sawaya; G N Fuller
Journal:  Nat Genet       Date:  2000-05       Impact factor: 38.330

3.  Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features.

Authors:  J S Smith; X Y Wang; J Qian; S M Hosek; B W Scheithauer; R B Jenkins; C D James
Journal:  J Neuropathol Exp Neurol       Date:  2000-06       Impact factor: 3.685

4.  Malignant astrocytoma cell attachment and migration to various matrix proteins is differentially sensitive to phosphoinositide 3-OH kinase inhibitors.

Authors:  J Ling; Z Liu; D Wang; C L Gladson
Journal:  J Cell Biochem       Date:  1999-06-15       Impact factor: 4.429

5.  Platelet-derived growth factor receptor beta and vascular endothelial growth factor receptor 2 bind to the beta 3 integrin through its extracellular domain.

Authors:  E Borges; Y Jan; E Ruoslahti
Journal:  J Biol Chem       Date:  2000-12-22       Impact factor: 5.157

6.  Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme.

Authors:  J A Kraus; N Glesmann; M Beck; D Krex; T Klockgether; G Schackert; U Schlegel
Journal:  J Neurooncol       Date:  2000-06       Impact factor: 4.130

Review 7.  Microtubule dynamics as a target in oncology.

Authors:  April L Risinger; Francis J Giles; Susan L Mooberry
Journal:  Cancer Treat Rev       Date:  2008-12-30       Impact factor: 12.111

8.  Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis.

Authors:  Haihao Zhu; Jaime Acquaviva; Pranatartiharan Ramachandran; Abraham Boskovitz; Steve Woolfenden; Rolf Pfannl; Roderick T Bronson; John W Chen; Ralph Weissleder; David E Housman; Al Charest
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

9.  Pyk2 and FAK differentially regulate progression of the cell cycle.

Authors:  J Zhao; C Zheng; J Guan
Journal:  J Cell Sci       Date:  2000-09       Impact factor: 5.285

10.  p125 focal adhesion kinase promotes malignant astrocytoma cell proliferation in vivo.

Authors:  D Wang; J R Grammer; C S Cobbs; J E Stewart; Z Liu; R Rhoden; T P Hecker; Q Ding; C L Gladson
Journal:  J Cell Sci       Date:  2000-12       Impact factor: 5.285

View more
  89 in total

Review 1.  Genomic profiling of glioblastoma: convergence of fundamental biologic tenets and novel insights.

Authors:  Kimberly Ng; Ryan Kim; Santosh Kesari; Bob Carter; Clark C Chen
Journal:  J Neurooncol       Date:  2011-10-16       Impact factor: 4.130

2.  Dual Receptor Targeting Cell Penetrating Peptide Modified Liposome for Glioma and Breast Cancer Postoperative Recurrence Therapy.

Authors:  Yue Qiu; Qianwen Yu; Yayuan Liu; Jiajing Tang; Xuhui Wang; Zhengze Lu; Zhuping Xu; Qin He
Journal:  Pharm Res       Date:  2018-04-26       Impact factor: 4.200

3.  REST represses miR-124 and miR-203 to regulate distinct oncogenic properties of glioblastoma stem cells.

Authors:  Anantha L Marisetty; Sanjay K Singh; Tran N Nguyen; Cristian Coarfa; Bin Liu; Sadhan Majumder
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

Review 4.  Cell phones and glioma risk: a review of the evidence.

Authors:  Courtney Corle; Milan Makale; Santosh Kesari
Journal:  J Neurooncol       Date:  2011-08-19       Impact factor: 4.130

5.  Biomarkers usher in era of personalized care for malignant glioma patients.

Authors:  Arnab Chakravarti; Kamalakannan Palanichamy; Erica Hlavin Bell
Journal:  CNS Oncol       Date:  2012-09

6.  [Preparation and characterization of paclitaxel microspheres in situ gel and its antitumor efficacy by local injection].

Authors:  Y Zhan; Y T DU; Z Z Yang; C L Zhang; X R Qi
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-06-18

7.  Glioma is formed by active Akt1 alone and promoted by active Rac1 in transgenic zebrafish.

Authors:  In Hye Jung; Ga Lam Leem; Dawoon E Jung; Min Hee Kim; Eun Young Kim; Se Hoon Kim; Hae-Chul Park; Seung Woo Park
Journal:  Neuro Oncol       Date:  2013-01-16       Impact factor: 12.300

8.  Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells.

Authors:  Yukti Choudhury; Felix Chang Tay; Dang Hoang Lam; Edwin Sandanaraj; Carol Tang; Beng-Ti Ang; Shu Wang
Journal:  J Clin Invest       Date:  2012-10-24       Impact factor: 14.808

9.  Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma.

Authors:  Merryl R Lobo; Sarah C Green; Matthias C Schabel; G Yancey Gillespie; Randall L Woltjer; Martin M Pike
Journal:  Neuro Oncol       Date:  2013-10-03       Impact factor: 12.300

10.  Effect of temozolomide on the U-118 glioma cell line.

Authors:  A Carmo; H Carvalheiro; I Crespo; I Nunes; M C Lopes
Journal:  Oncol Lett       Date:  2011-09-02       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.